nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—ADRB3—obesity	0.145	0.546	CbGaD
Droxidopa—Metaraminol—Phenylpropanolamine—obesity	0.141	0.573	CrCrCtD
Droxidopa—Levonordefrin—Phenylpropanolamine—obesity	0.105	0.427	CrCrCtD
Droxidopa—ADRB1—obesity	0.0657	0.247	CbGaD
Droxidopa—ADRB2—obesity	0.0553	0.207	CbGaD
Droxidopa—SLC6A2—Diethylpropion—obesity	0.0316	0.0865	CbGbCtD
Droxidopa—ADRA1B—Phendimetrazine—obesity	0.0263	0.0718	CbGbCtD
Droxidopa—SLC6A2—Sibutramine—obesity	0.024	0.0655	CbGbCtD
Droxidopa—SLC6A2—Phendimetrazine—obesity	0.024	0.0655	CbGbCtD
Droxidopa—ADRB2—Phenylpropanolamine—obesity	0.0207	0.0566	CbGbCtD
Droxidopa—ADRA1A—Phendimetrazine—obesity	0.0207	0.0566	CbGbCtD
Droxidopa—ADRB1—Phenylpropanolamine—obesity	0.0204	0.0558	CbGbCtD
Droxidopa—ADRA2C—Methamphetamine—obesity	0.0198	0.0543	CbGbCtD
Droxidopa—ADRA2B—Methamphetamine—obesity	0.0188	0.0515	CbGbCtD
Droxidopa—SLC6A2—Phentermine—obesity	0.0182	0.0497	CbGbCtD
Droxidopa—SLC6A2—Benzphetamine—obesity	0.0182	0.0497	CbGbCtD
Droxidopa—SLC6A2—Phenylpropanolamine—obesity	0.0173	0.0474	CbGbCtD
Droxidopa—ADRA2A—Benzphetamine—obesity	0.0164	0.0448	CbGbCtD
Droxidopa—ADRA1A—Benzphetamine—obesity	0.0157	0.0429	CbGbCtD
Droxidopa—ADRA2A—Phenylpropanolamine—obesity	0.0156	0.0427	CbGbCtD
Droxidopa—SLC6A2—Bupropion—obesity	0.0154	0.0422	CbGbCtD
Droxidopa—ADRA1A—Phenylpropanolamine—obesity	0.015	0.041	CbGbCtD
Droxidopa—SLC6A2—Methamphetamine—obesity	0.0145	0.0397	CbGbCtD
Droxidopa—ADRA2A—Methamphetamine—obesity	0.0131	0.0358	CbGbCtD
Droxidopa—ADRB3—brown adipose tissue—obesity	0.00485	0.232	CbGeAlD
Droxidopa—Blood pressure increased—Phendimetrazine—obesity	0.00204	0.0748	CcSEcCtD
Droxidopa—PAH—gall bladder—obesity	0.002	0.0959	CbGeAlD
Droxidopa—SLC6A2—sympathetic nervous system—obesity	0.00195	0.0933	CbGeAlD
Droxidopa—Blood pressure increased—Phenylpropanolamine—obesity	0.00174	0.0639	CcSEcCtD
Droxidopa—Blood pressure increased—Diethylpropion—obesity	0.00145	0.0532	CcSEcCtD
Droxidopa—SLC6A2—autonomic nervous system—obesity	0.00131	0.0627	CbGeAlD
Droxidopa—DDC—hindbrain—obesity	0.00116	0.0554	CbGeAlD
Droxidopa—Arrhythmia—Phenylpropanolamine—obesity	0.000781	0.0287	CcSEcCtD
Droxidopa—Blood pressure increased—Sibutramine—obesity	0.000737	0.027	CcSEcCtD
Droxidopa—DDC—respiratory system—obesity	0.000707	0.0339	CbGeAlD
Droxidopa—ADRB3—adipose tissue—obesity	0.000654	0.0313	CbGeAlD
Droxidopa—PAH—endocrine gland—obesity	0.000652	0.0312	CbGeAlD
Droxidopa—Arrhythmia—Diethylpropion—obesity	0.00065	0.0239	CcSEcCtD
Droxidopa—Blood pressure increased—Bupropion—obesity	0.000642	0.0236	CcSEcCtD
Droxidopa—Hypertension—Phentermine—obesity	0.000629	0.0231	CcSEcCtD
Droxidopa—Confusional state—Phenylpropanolamine—obesity	0.000626	0.023	CcSEcCtD
Droxidopa—Cardiac failure congestive—Sibutramine—obesity	0.00059	0.0216	CcSEcCtD
Droxidopa—PAH—liver—obesity	0.000588	0.0281	CbGeAlD
Droxidopa—Dizziness—Methamphetamine—obesity	0.000547	0.0201	CcSEcCtD
Droxidopa—Dizziness—Benzphetamine—obesity	0.000528	0.0194	CcSEcCtD
Droxidopa—Headache—Methamphetamine—obesity	0.000518	0.019	CcSEcCtD
Droxidopa—ADRA1A—hindbrain—obesity	0.000513	0.0246	CbGeAlD
Droxidopa—Feeling abnormal—Phenylpropanolamine—obesity	0.000512	0.0188	CcSEcCtD
Droxidopa—Headache—Benzphetamine—obesity	0.0005	0.0183	CcSEcCtD
Droxidopa—Confusional state—Cimetidine—obesity	0.000496	0.0182	CcSEcCtD
Droxidopa—Dizziness—Phendimetrazine—obesity	0.000481	0.0176	CcSEcCtD
Droxidopa—Nausea—Benzphetamine—obesity	0.000474	0.0174	CcSEcCtD
Droxidopa—Headache—Phendimetrazine—obesity	0.000455	0.0167	CcSEcCtD
Droxidopa—Nausea—Phendimetrazine—obesity	0.000432	0.0158	CcSEcCtD
Droxidopa—DDC—adrenal gland—obesity	0.000429	0.0205	CbGeAlD
Droxidopa—Feeling abnormal—Diethylpropion—obesity	0.000426	0.0156	CcSEcCtD
Droxidopa—Urinary tract infection—Orlistat—obesity	0.000414	0.0152	CcSEcCtD
Droxidopa—Dizziness—Phenylpropanolamine—obesity	0.000411	0.0151	CcSEcCtD
Droxidopa—Feeling abnormal—Cimetidine—obesity	0.000405	0.0149	CcSEcCtD
Droxidopa—Urinary tract infection—Sibutramine—obesity	0.000401	0.0147	CcSEcCtD
Droxidopa—Isoprenaline—PIK3R1—obesity	0.000397	0.149	CrCbGaD
Droxidopa—Dizziness—Phentermine—obesity	0.000393	0.0144	CcSEcCtD
Droxidopa—Headache—Phentermine—obesity	0.000372	0.0137	CcSEcCtD
Droxidopa—DDC—endocrine gland—obesity	0.000372	0.0178	CbGeAlD
Droxidopa—Nausea—Phenylpropanolamine—obesity	0.000369	0.0135	CcSEcCtD
Droxidopa—Nausea—Phentermine—obesity	0.000353	0.013	CcSEcCtD
Droxidopa—Urinary tract infection—Bupropion—obesity	0.000349	0.0128	CcSEcCtD
Droxidopa—Dizziness—Diethylpropion—obesity	0.000342	0.0125	CcSEcCtD
Droxidopa—SLC6A2—respiratory system—obesity	0.000337	0.0161	CbGeAlD
Droxidopa—DDC—liver—obesity	0.000335	0.016	CbGeAlD
Droxidopa—Arrhythmia—Sibutramine—obesity	0.000331	0.0121	CcSEcCtD
Droxidopa—SLC16A10—adipose tissue—obesity	0.000328	0.0157	CbGeAlD
Droxidopa—Dizziness—Cimetidine—obesity	0.000325	0.0119	CcSEcCtD
Droxidopa—Headache—Diethylpropion—obesity	0.000324	0.0119	CcSEcCtD
Droxidopa—Headache—Cimetidine—obesity	0.000308	0.0113	CcSEcCtD
Droxidopa—Nausea—Diethylpropion—obesity	0.000307	0.0113	CcSEcCtD
Droxidopa—ADRB1—cardiovascular system—obesity	0.000303	0.0145	CbGeAlD
Droxidopa—Nausea—Cimetidine—obesity	0.000292	0.0107	CcSEcCtD
Droxidopa—Syncope—Sibutramine—obesity	0.000289	0.0106	CcSEcCtD
Droxidopa—Arrhythmia—Bupropion—obesity	0.000288	0.0106	CcSEcCtD
Droxidopa—ADRA1D—endocrine gland—obesity	0.000287	0.0137	CbGeAlD
Droxidopa—Loss of consciousness—Sibutramine—obesity	0.000283	0.0104	CcSEcCtD
Droxidopa—Hypertension—Sibutramine—obesity	0.000278	0.0102	CcSEcCtD
Droxidopa—ADRB1—adipose tissue—obesity	0.000268	0.0128	CbGeAlD
Droxidopa—Confusional state—Sibutramine—obesity	0.000265	0.00972	CcSEcCtD
Droxidopa—Shock—Sibutramine—obesity	0.000259	0.00949	CcSEcCtD
Droxidopa—SLC16A10—endocrine gland—obesity	0.000255	0.0122	CbGeAlD
Droxidopa—ADRA2A—islet of Langerhans—obesity	0.000252	0.0121	CbGeAlD
Droxidopa—Syncope—Bupropion—obesity	0.000252	0.00924	CcSEcCtD
Droxidopa—ADRA2C—adrenal cortex—obesity	0.000251	0.012	CbGeAlD
Droxidopa—Loss of consciousness—Bupropion—obesity	0.000247	0.00905	CcSEcCtD
Droxidopa—Hypertension—Bupropion—obesity	0.000242	0.00889	CcSEcCtD
Droxidopa—ADRA1A—cardiovascular system—obesity	0.00024	0.0115	CbGeAlD
Droxidopa—Confusional state—Bupropion—obesity	0.000231	0.00848	CcSEcCtD
Droxidopa—SLC16A10—liver—obesity	0.00023	0.011	CbGeAlD
Droxidopa—Shock—Bupropion—obesity	0.000225	0.00827	CcSEcCtD
Droxidopa—Feeling abnormal—Orlistat—obesity	0.000224	0.00821	CcSEcCtD
Droxidopa—Urinary tract infection—Topiramate—obesity	0.000223	0.00816	CcSEcCtD
Droxidopa—Feeling abnormal—Sibutramine—obesity	0.000217	0.00795	CcSEcCtD
Droxidopa—ADRA1A—adipose tissue—obesity	0.000212	0.0101	CbGeAlD
Droxidopa—ADRB1—endocrine gland—obesity	0.000208	0.00996	CbGeAlD
Droxidopa—SLC6A2—adrenal gland—obesity	0.000204	0.00977	CbGeAlD
Droxidopa—ADRA2C—pituitary gland—obesity	0.000202	0.00969	CbGeAlD
Droxidopa—ADRA2C—adipose tissue—obesity	0.000202	0.00965	CbGeAlD
Droxidopa—ADRA1A—adrenal gland—obesity	0.00019	0.00908	CbGeAlD
Droxidopa—Feeling abnormal—Bupropion—obesity	0.000189	0.00693	CcSEcCtD
Droxidopa—ADRA2C—adrenal gland—obesity	0.000181	0.00866	CbGeAlD
Droxidopa—Dizziness—Orlistat—obesity	0.00018	0.00659	CcSEcCtD
Droxidopa—Methyldopa—COMT—obesity	0.000179	0.0676	CrCbGaD
Droxidopa—SLC6A2—endocrine gland—obesity	0.000177	0.00847	CbGeAlD
Droxidopa—Dizziness—Sibutramine—obesity	0.000174	0.00638	CcSEcCtD
Droxidopa—Headache—Orlistat—obesity	0.00017	0.00624	CcSEcCtD
Droxidopa—Headache—Sibutramine—obesity	0.000165	0.00604	CcSEcCtD
Droxidopa—ADRA1A—endocrine gland—obesity	0.000165	0.00788	CbGeAlD
Droxidopa—ADRA2A—pituitary gland—obesity	0.000162	0.00773	CbGeAlD
Droxidopa—Nausea—Orlistat—obesity	0.000161	0.00592	CcSEcCtD
Droxidopa—ADRA2A—adipose tissue—obesity	0.000161	0.0077	CbGeAlD
Droxidopa—Syncope—Topiramate—obesity	0.00016	0.00589	CcSEcCtD
Droxidopa—Loss of consciousness—Topiramate—obesity	0.000157	0.00577	CcSEcCtD
Droxidopa—Nausea—Sibutramine—obesity	0.000156	0.00573	CcSEcCtD
Droxidopa—Isoetarine—ADRB1—obesity	0.000156	0.0588	CrCbGaD
Droxidopa—Hypertension—Topiramate—obesity	0.000154	0.00567	CcSEcCtD
Droxidopa—Dizziness—Bupropion—obesity	0.000152	0.00556	CcSEcCtD
Droxidopa—ADRA1A—liver—obesity	0.000148	0.0071	CbGeAlD
Droxidopa—Confusional state—Topiramate—obesity	0.000147	0.0054	CcSEcCtD
Droxidopa—ADRA2A—adrenal gland—obesity	0.000144	0.00691	CbGeAlD
Droxidopa—Shock—Topiramate—obesity	0.000144	0.00527	CcSEcCtD
Droxidopa—Headache—Bupropion—obesity	0.000144	0.00527	CcSEcCtD
Droxidopa—Isoprenaline—ADRB3—obesity	0.000143	0.054	CrCbGaD
Droxidopa—ADRA2C—liver—obesity	0.000141	0.00677	CbGeAlD
Droxidopa—Nausea—Bupropion—obesity	0.000136	0.00499	CcSEcCtD
Droxidopa—Norepinephrine—ADRB3—obesity	0.000133	0.05	CrCbGaD
Droxidopa—Isoetarine—ADRB2—obesity	0.000131	0.0494	CrCbGaD
Droxidopa—ADRA2A—endocrine gland—obesity	0.000125	0.00599	CbGeAlD
Droxidopa—Epinephrine—ADRB3—obesity	0.00012	0.0454	CrCbGaD
Droxidopa—Feeling abnormal—Topiramate—obesity	0.00012	0.00441	CcSEcCtD
Droxidopa—Mesalazine—PPARG—obesity	0.000101	0.038	CrCbGaD
Droxidopa—Dizziness—Topiramate—obesity	9.65e-05	0.00354	CcSEcCtD
Droxidopa—Headache—Topiramate—obesity	9.15e-05	0.00336	CcSEcCtD
Droxidopa—Dopamine—COMT—obesity	8.76e-05	0.033	CrCbGaD
Droxidopa—Nausea—Topiramate—obesity	8.67e-05	0.00318	CcSEcCtD
Droxidopa—Norepinephrine—SLC22A1—obesity	7.91e-05	0.0298	CrCbGaD
Droxidopa—L-DOPA—DRD4—obesity	7.64e-05	0.0288	CrCbGaD
Droxidopa—Dopamine—SLC22A1—obesity	7.35e-05	0.0277	CrCbGaD
Droxidopa—Epinephrine—SLC22A1—obesity	7.17e-05	0.027	CrCbGaD
Droxidopa—Dopamine—DRD4—obesity	7.1e-05	0.0267	CrCbGaD
Droxidopa—Isoprenaline—ADRB1—obesity	6.48e-05	0.0244	CrCbGaD
Droxidopa—L-DOPA—DRD1—obesity	6.46e-05	0.0243	CrCbGaD
Droxidopa—Dopamine—DRD1—obesity	6.01e-05	0.0226	CrCbGaD
Droxidopa—Norepinephrine—ADRB1—obesity	6e-05	0.0226	CrCbGaD
Droxidopa—Dopamine—ADRB1—obesity	5.58e-05	0.021	CrCbGaD
Droxidopa—Isoprenaline—ADRB2—obesity	5.45e-05	0.0205	CrCbGaD
Droxidopa—Epinephrine—ADRB1—obesity	5.44e-05	0.0205	CrCbGaD
Droxidopa—Aminosalicylic Acid—PTGS2—obesity	5.43e-05	0.0205	CrCbGaD
Droxidopa—Epinephrine—TNF—obesity	5.17e-05	0.0195	CrCbGaD
Droxidopa—Norepinephrine—ADRB2—obesity	5.05e-05	0.019	CrCbGaD
Droxidopa—Epinephrine—ADRB2—obesity	4.58e-05	0.0172	CrCbGaD
Droxidopa—L-DOPA—DRD2—obesity	4.56e-05	0.0172	CrCbGaD
Droxidopa—Norepinephrine—DRD2—obesity	4.56e-05	0.0172	CrCbGaD
Droxidopa—Mesalazine—PTGS2—obesity	4.26e-05	0.016	CrCbGaD
Droxidopa—Dopamine—SLC6A4—obesity	4.26e-05	0.016	CrCbGaD
Droxidopa—Dopamine—DRD2—obesity	4.24e-05	0.016	CrCbGaD
Droxidopa—ADRB2—Signaling Pathways—POMC—obesity	1.25e-06	1.77e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TYK2—obesity	1.25e-06	1.77e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—MYC—obesity	1.25e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—INS—obesity	1.25e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3CG—obesity	1.25e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—TGFB1—obesity	1.25e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCL2—obesity	1.24e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—RHOA—obesity	1.24e-06	1.75e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PIK3R1—obesity	1.24e-06	1.75e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—NOS3—obesity	1.24e-06	1.75e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IRS2—obesity	1.23e-06	1.74e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PRKCD—obesity	1.23e-06	1.74e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IGF1—obesity	1.23e-06	1.74e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AGT—obesity	1.23e-06	1.74e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—AKT2—obesity	1.23e-06	1.74e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IRS1—obesity	1.23e-06	1.74e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCL2—obesity	1.23e-06	1.73e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PIK3R1—obesity	1.23e-06	1.73e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NOS3—obesity	1.23e-06	1.73e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3CG—obesity	1.23e-06	1.73e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IGF1—obesity	1.22e-06	1.73e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—AKT2—obesity	1.22e-06	1.73e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IRS1—obesity	1.21e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3CG—obesity	1.21e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—LEP—obesity	1.21e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—APOE—obesity	1.21e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR2A—obesity	1.21e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IGF1—obesity	1.21e-06	1.7e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—AKT2—obesity	1.21e-06	1.7e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—C3—obesity	1.21e-06	1.7e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CAV1—obesity	1.2e-06	1.69e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—APOA1—obesity	1.19e-06	1.69e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—POMC—obesity	1.19e-06	1.68e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PIK3CD—obesity	1.18e-06	1.67e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—INS—obesity	1.18e-06	1.67e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PIK3CD—obesity	1.17e-06	1.66e-05	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—PIK3CA—obesity	1.17e-06	1.66e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—SERPINE1—obesity	1.17e-06	1.66e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—PIK3CA—obesity	1.17e-06	1.65e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PPARG—obesity	1.17e-06	1.65e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—POMC—obesity	1.17e-06	1.65e-05	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—PIK3CA—obesity	1.16e-06	1.64e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—INS—obesity	1.16e-06	1.64e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCL2—obesity	1.16e-06	1.64e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—SERPINE1—obesity	1.16e-06	1.64e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PIK3CD—obesity	1.16e-06	1.64e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ESR1—obesity	1.15e-06	1.63e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—POMC—obesity	1.15e-06	1.63e-05	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—PIK3CA—obesity	1.15e-06	1.62e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IRS2—obesity	1.15e-06	1.62e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—INS—obesity	1.15e-06	1.62e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—SERPINE1—obesity	1.15e-06	1.62e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AGT—obesity	1.15e-06	1.62e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCL2—obesity	1.14e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PIK3CB—obesity	1.14e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IGF1—obesity	1.14e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—AKT2—obesity	1.14e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—AKT1—obesity	1.14e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TYK2—obesity	1.14e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PRKCB—obesity	1.14e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—F2—obesity	1.14e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PIK3CB—obesity	1.13e-06	1.6e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MTOR—obesity	1.13e-06	1.6e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PTGS2—obesity	1.13e-06	1.6e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—RHOA—obesity	1.13e-06	1.6e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TYK2—obesity	1.13e-06	1.6e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—BAD—obesity	1.13e-06	1.59e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IGF1—obesity	1.12e-06	1.59e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—AKT2—obesity	1.12e-06	1.59e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—LEP—obesity	1.12e-06	1.59e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—APOE—obesity	1.12e-06	1.59e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—RHOA—obesity	1.12e-06	1.58e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PIK3R1—obesity	1.12e-06	1.58e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NOS3—obesity	1.12e-06	1.58e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TYK2—obesity	1.11e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CAV1—obesity	1.11e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—APOA1—obesity	1.11e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NOS3—obesity	1.11e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PIK3R1—obesity	1.11e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—RHOA—obesity	1.11e-06	1.56e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3CD—obesity	1.1e-06	1.55e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NOS3—obesity	1.09e-06	1.55e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PIK3R1—obesity	1.09e-06	1.55e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CG—obesity	1.09e-06	1.54e-05	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—PIK3CA—obesity	1.09e-06	1.53e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—SERPINE1—obesity	1.08e-06	1.53e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3CD—obesity	1.08e-06	1.52e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IRS1—obesity	1.08e-06	1.52e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ESR1—obesity	1.07e-06	1.51e-05	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—PIK3CA—obesity	1.07e-06	1.51e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—SERPINE1—obesity	1.07e-06	1.51e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—PIK3CA—obesity	1.07e-06	1.51e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3CD—obesity	1.06e-06	1.5e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—PIK3CA—obesity	1.06e-06	1.5e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PRKCB—obesity	1.06e-06	1.5e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—F2—obesity	1.06e-06	1.5e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—PIK3CA—obesity	1.06e-06	1.49e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TYK2—obesity	1.05e-06	1.49e-05	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—AKT1—obesity	1.05e-06	1.49e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ALB—obesity	1.05e-06	1.49e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—RHOA—obesity	1.05e-06	1.48e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—BAD—obesity	1.05e-06	1.48e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—PIK3CA—obesity	1.04e-06	1.47e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TYK2—obesity	1.04e-06	1.47e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—POMC—obesity	1.04e-06	1.47e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—IL6—obesity	1.04e-06	1.46e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NOS3—obesity	1.04e-06	1.46e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3R1—obesity	1.04e-06	1.46e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MTOR—obesity	1.03e-06	1.46e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PIK3CB—obesity	1.03e-06	1.46e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—INS—obesity	1.03e-06	1.46e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—RHOA—obesity	1.03e-06	1.45e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PIK3CB—obesity	1.02e-06	1.45e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MTOR—obesity	1.02e-06	1.45e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NOS3—obesity	1.02e-06	1.44e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3R1—obesity	1.02e-06	1.44e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCL2—obesity	1.02e-06	1.43e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CG—obesity	1.01e-06	1.43e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PIK3CB—obesity	1.01e-06	1.43e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MTOR—obesity	1.01e-06	1.43e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3R1—obesity	1.01e-06	1.42e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—NOS3—obesity	1.01e-06	1.42e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IRS1—obesity	1e-06	1.41e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IGF1—obesity	9.98e-07	1.41e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AKT2—obesity	9.97e-07	1.41e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—PIK3CA—obesity	9.86e-07	1.39e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MMP9—obesity	9.85e-07	1.39e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—PIK3CA—obesity	9.7e-07	1.37e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—POMC—obesity	9.64e-07	1.36e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—INS—obesity	9.59e-07	1.35e-05	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—AKT1—obesity	9.58e-07	1.35e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CD—obesity	9.58e-07	1.35e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MAPK8—obesity	9.58e-07	1.35e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MTOR—obesity	9.56e-07	1.35e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3CB—obesity	9.56e-07	1.35e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—AKT1—obesity	9.55e-07	1.35e-05	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—AKT1—obesity	9.5e-07	1.34e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—PIK3CA—obesity	9.49e-07	1.34e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—SERPINE1—obesity	9.48e-07	1.34e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—IL6—obesity	9.43e-07	1.33e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCL2—obesity	9.43e-07	1.33e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3CB—obesity	9.4e-07	1.33e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MTOR—obesity	9.4e-07	1.33e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—IL6—obesity	9.39e-07	1.33e-05	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—AKT1—obesity	9.37e-07	1.32e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—IL6—obesity	9.35e-07	1.32e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3CB—obesity	9.28e-07	1.31e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IGF1—obesity	9.27e-07	1.31e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AKT2—obesity	9.27e-07	1.31e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—IL6—obesity	9.23e-07	1.3e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TYK2—obesity	9.22e-07	1.3e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PTGS2—obesity	9.2e-07	1.3e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—RHOA—obesity	9.14e-07	1.29e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3R1—obesity	9.05e-07	1.28e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NOS3—obesity	9.05e-07	1.28e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MMP9—obesity	8.97e-07	1.27e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CD—obesity	8.9e-07	1.26e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MMP9—obesity	8.89e-07	1.26e-05	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—AKT1—obesity	8.87e-07	1.25e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—PIK3CA—obesity	8.82e-07	1.25e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—SERPINE1—obesity	8.81e-07	1.24e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MMP9—obesity	8.78e-07	1.24e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—STAT3—obesity	8.76e-07	1.24e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—IL6—obesity	8.73e-07	1.23e-05	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—AKT1—obesity	8.73e-07	1.23e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MAPK8—obesity	8.73e-07	1.23e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—AKT1—obesity	8.7e-07	1.23e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—AKT1—obesity	8.66e-07	1.22e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MAPK8—obesity	8.65e-07	1.22e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—AKT1—obesity	8.62e-07	1.22e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—PIK3CA—obesity	8.62e-07	1.22e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—IL6—obesity	8.59e-07	1.21e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TYK2—obesity	8.57e-07	1.21e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MAPK8—obesity	8.54e-07	1.21e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—AKT1—obesity	8.51e-07	1.2e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—RHOA—obesity	8.5e-07	1.2e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3R1—obesity	8.41e-07	1.19e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NOS3—obesity	8.41e-07	1.19e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MTOR—obesity	8.35e-07	1.18e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CB—obesity	8.35e-07	1.18e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MMP9—obesity	8.31e-07	1.17e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MMP9—obesity	8.17e-07	1.15e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MYC—obesity	8.14e-07	1.15e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TGFB1—obesity	8.12e-07	1.15e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MAPK8—obesity	8.08e-07	1.14e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—AKT1—obesity	8.05e-07	1.14e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—PIK3CA—obesity	8.01e-07	1.13e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—STAT3—obesity	7.98e-07	1.13e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MAPK8—obesity	7.95e-07	1.12e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—AKT1—obesity	7.93e-07	1.12e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—STAT3—obesity	7.91e-07	1.12e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—STAT3—obesity	7.8e-07	1.1e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CB—obesity	7.76e-07	1.1e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MTOR—obesity	7.76e-07	1.1e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—AKT1—obesity	7.75e-07	1.1e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—IL6—obesity	7.63e-07	1.08e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MYC—obesity	7.41e-07	1.05e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TGFB1—obesity	7.4e-07	1.04e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—STAT3—obesity	7.38e-07	1.04e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MYC—obesity	7.35e-07	1.04e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TGFB1—obesity	7.33e-07	1.04e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—STAT3—obesity	7.27e-07	1.03e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MMP9—obesity	7.26e-07	1.03e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MYC—obesity	7.25e-07	1.02e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TGFB1—obesity	7.23e-07	1.02e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—AKT1—obesity	7.2e-07	1.02e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—IL6—obesity	7.09e-07	1e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MAPK8—obesity	7.06e-07	9.98e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—AKT1—obesity	7.04e-07	9.95e-06	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PIK3CA—obesity	6.97e-07	9.84e-06	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PIK3CA—obesity	6.91e-07	9.76e-06	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MYC—obesity	6.86e-07	9.69e-06	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TGFB1—obesity	6.84e-07	9.67e-06	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MYC—obesity	6.75e-07	9.54e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MMP9—obesity	6.75e-07	9.53e-06	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TGFB1—obesity	6.74e-07	9.52e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MAPK8—obesity	6.56e-07	9.27e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—AKT1—obesity	6.54e-07	9.24e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—STAT3—obesity	6.46e-07	9.12e-06	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PIK3CA—obesity	6.29e-07	8.89e-06	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PIK3CA—obesity	6.24e-07	8.81e-06	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PIK3CA—obesity	6.16e-07	8.7e-06	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL6—obesity	6.12e-07	8.64e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MYC—obesity	6e-07	8.47e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—STAT3—obesity	6e-07	8.47e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TGFB1—obesity	5.98e-07	8.45e-06	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3CA—obesity	5.82e-07	8.23e-06	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3CA—obesity	5.73e-07	8.1e-06	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—AKT1—obesity	5.69e-07	8.04e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3CA—obesity	5.66e-07	7.99e-06	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—AKT1—obesity	5.64e-07	7.97e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MYC—obesity	5.57e-07	7.87e-06	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL6—obesity	5.57e-07	7.87e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TGFB1—obesity	5.56e-07	7.86e-06	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL6—obesity	5.52e-07	7.8e-06	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL6—obesity	5.45e-07	7.7e-06	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL6—obesity	5.16e-07	7.29e-06	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—AKT1—obesity	5.14e-07	7.26e-06	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—AKT1—obesity	5.09e-07	7.2e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CA—obesity	5.09e-07	7.19e-06	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL6—obesity	5.08e-07	7.17e-06	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—AKT1—obesity	5.03e-07	7.11e-06	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—AKT1—obesity	4.76e-07	6.72e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CA—obesity	4.73e-07	6.68e-06	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—AKT1—obesity	4.68e-07	6.62e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—AKT1—obesity	4.62e-07	6.53e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL6—obesity	4.51e-07	6.37e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL6—obesity	4.19e-07	5.92e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AKT1—obesity	4.16e-07	5.88e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AKT1—obesity	3.86e-07	5.46e-06	CbGpPWpGaD
